Indices
|
Omega-3 (n = 30)
|
Placebo (n = 30)
|
P†
|
P††
|
---|
AIP
| | | |
0.13
|
Baseline
|
0.49 ± 0.22
|
0.44 ± 0.19
|
0.36
|
Week 12
|
0.38 ± 0.28
|
0.41 ± 0.27
|
0.67
|
P
|
0.007
|
0.33
| |
Mean change
|
−0.11 ± 0.20
|
−0.03 ± 0.16
|
0.10
|
Castelli risk index I
| | | |
0.46
|
Baseline
|
3.63 ± 0.9
|
3.41 ± 0.7
|
0.31
|
Week 12
|
3.38 ± 0.9
|
3.34 ± 0.7
|
0.88
|
P
|
0.05
|
0.62
| |
Mean change
|
−0.25 ± 0.6
|
−0.07 ± 0.7
|
0.29
|
Castelli risk index II
| | | |
0.70
|
Baseline
|
2.11 ± 0.6
|
1.97 ± 0.5
|
0.55
|
Week 12
|
1.87 ± 0.6
|
1.83 ± 0.5
|
0.81
|
P
|
0.01
|
0.15
| |
Mean change
|
−0.24 ± 0.5
|
−0.14 ± 0.5
|
0.47
|
AC
| | | |
0.40
|
Baseline
|
2.63 ± 0.9
|
2.41 ± 0.7
|
0.31
|
Week 12
|
2.38 ± 0.9
|
2.34 ± 0.7
|
0.88
|
P
|
0.05
|
0.62
| |
Mean change
|
−0.25 ± 0.6
|
−0.07 ± 0.7
|
0.29
|
- P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD)
- P: resulted from comparisons within groups by paired t-test
- P†: resulted from comparisons between two groups by independent t-test
- P††: resulted from comparing the mean change from baseline between groups using univariate ANCOVA after adjusting for energy intake and weight change
- NAFLD Non-alcoholic fatty liver disease, AIP Atherogenic index of plasma, AC Atherogenic coefficient